Cutaneous gamma/delta T-cell lymphoma treated with radiation and denileukin diftitox.
Cutaneous gamma/delta T-cell lymphoma (CGD-TCL) is a rare and usually fatal lymphoma that is generally resistant to chemotherapy and radiation. It has recently been included as a provisional entity in the combined 2005 World Health Organization-European Organization for Research and Treatment of Cancer consensus classification. Subcutaneous panniculitic T-cell lymphomas with a gamma/delta T-cell receptor phenotype are now distinguished from the less aggressive alpha/beta panniculitic T-cell lymphoma. We describe a patient with deep ulcers initially diagnosed as pyoderma gangrenosum, which was reclassified as CGD-TCL. Local radiation followed by weekly infusions of denileukin diftitox put the patient into remission.
Vidulich
Kelley
K
Department of Dermatology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA. kvidulich@hotmail.com
Jones
Dan
D
Duvic
Madeleine
M
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D004167:Diphtheria Toxin / Q000627:therapeutic use*; D006526:Hepatitis C / Q000150:complications; D006801:Humans; D007376:Interleukin-2 / Q000627:therapeutic use*; D053645:Interleukin-2 Receptor alpha Subunit / Q000032:analysis; D016410:Lymphoma, T-Cell, Cutaneous / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D016692:Receptors, Antigen, T-Cell, gamma-delta / Q000032:analysis*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000628:therapy*
D000970:Antineoplastic Agents; D004167:Diphtheria Toxin; D007376:Interleukin-2; D053645:Interleukin-2 Receptor alpha Subunit; D016692:Receptors, Antigen, T-Cell, gamma-delta; D011993:Recombinant Fusion Proteins; C078456:denileukin diftitox